Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations

• Status: Not yet recruiting
• Trial end date: 2027-09-01
• Target enrollment: 0
• Participant gender: All

Summary

People living with chronic obstructive pulmonary disease (COPD) may experience worsening of symptoms such as shortness of breath, cough and wheezing in addition to changes that may be expected for having COPD. The worsening of symptoms is called exacerbations or flare-ups and can be debilitating and frightening, requiring additional treatment, often with azithromycin. This is an antibiotic medicine that also has anti-inflammatory properties. It is prescribed as long-term prevention to reduce the risk of flare-ups. Some people may be affected by side effects from azithromycin. Antibiotic resistance is another concern, especially when using azithromycin for prevention rather than to treat active infection.

It is currently unclear as to whether people should be advised to stop taking azithromycin once COPD has stabilised, or to stop it over the summer when fewer flare-ups happen. It is also not known if azithromycin is more effective in some people or more likely to cause side effects in others. Given these uncertainties, it is challenging to know how best to use azithromycin in managing COPD. Azithromycin is a valuable antibiotic, and should be prescribed where it has benefit but avoid unnecessary side effects and reduce the chances of bacteria becoming resistant to it.

The purpose of this trial is to be able to gain results to answer these questions, and to establish the effects of stopping azithromycin in people whose COPD has stabilised, who have been taking it for at least 3 months. This trial will compare continuing azithromycin with stopping it completely, or stopping over the summer only, continuing over the winter. The investigators will compare the effects of these three treatments in the trial on flare-ups, symptoms and quality of life, and find out what factors may affect how individual participants respond to them.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr Ian B Wilkinson
• Collaborators: Eramol (UK) Ltd.; Imperial College London; Liverpool Heart and Chest Hospital NHS Foundation Trust; Liverpool School of Tropical Medicine; National Institute for Health Research, United Kingdom; Newcastle University; NHS Greater Glasgow and Clyde; NHS Sunderland Clinical Commissioning Group; Nottingham City Hospital; Red Graphic; Royal Brompton & Harefield NHS Foundation Trust; Sealed Envelope Ltd.; Swansea University; University College London Hospitals; University of Aberdeen; University of Cambridge; University of East Anglia; WGK Clinical Services Ltd.
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Be able and willing to provide informed consent.

• Have an established clinical diagnosis of COPD and be receiving prophylactic azithromycin for ≥ (at least) 3 months to reduce COPD exacerbations.

• Have a self-reported smoking history of ≥ (at least) 10 pack years.

• Be aged >= 40 years.

• Have clinically stable COPD, i.e. no COPD exacerbation for at least 6 weeks.

Exclusion Criteria:

• Known hypersensitivity to any of the trial drugs or excipients.

• Current breast feeding, pregnancy or planned pregnancy during the trial.

• Any medical history or clinically relevant abnormality that makes participant ineligible for inclusion because of a safety concern relating to continuing or discontinuing azithromycin or other considerations.

• Known immunodeficiency requiring immunoglobulin/specific antibody therapy.

• Azithromycin prophylaxis prescribed for non-COPD condition.

• Active participation in COPD Clinical Trial of an Investigational Medicinal Product (CTIMP).

Electrocardiograms (ECGs) will not be a trial assessment nor entry requirement.